On Thursday, Novartis won European approval for its injectable Xolair to treat chronic hives--the first such product cleared there for patients who don't respond to antihistamines alone.
Incyte CEO Hervé Hoppenot has been telling anyone who'll listen that his biotech is undervalued and underestimated, and now, with promising late-stage results for its lead drug in a rare blood cancer, the company has a shot at blockbuster sales alongside partner Novartis.
As the company points out, it's the only product cleared for patients whose chronic spontaneous urticaria haven't responded to antihistamines.
After their antitrust-fighting colleagues levied $251 million in fines against Swiss drugmakers Roche and Novartis on allegations that they colluded to protect sales of their eye drug, Italian prosecutors are now investigating possible market manipulation and fraud, according to Reuters.
Novartis is making its way into late-stage studies for the orphan drug bimagrumab, and co-developer MorphoSys said sales of the muscle-growing treatment could peak at $4 billion a year.
Doctors have been prescribing Roche's cancer drug Avastin off-label to treat some of the same vision problems as its eye drug, Lucentis. Now, Italy's antitrust authority has fined Roche and marketing partner Novartis, accusing them of colluding to push doctors toward the pricier option--claims the pair denies.
The earnings reports for the biggest of Big Pharma are all in. Bayer reported last week, making it possible to see how they stacked up as they came into the new year. There are no big surprises....
Novartis Chairman Joerg Reinhardt may be chatting with his colleagues at Roche. His company may want to work more closely with its hometown rival. But joining forces in a merger? No, thank you.
Unlike every other Big Pharma company in the world, Novartis tends to prefer to communicate rather selectively when it chops a facility here or winnows out its ranks over there in its global structure.
Johnson & Johnson was cautiously lauded for its clinical trial data-sharing initiative, but Roche's project was pilloried. Now Novartis has joined its Swiss peer in rolling out an underwhelming transparency program.